76.22
Edwards Lifesciences Corp stock is traded at $76.22, with a volume of 3.59M.
It is up +1.64% in the last 24 hours and up +0.24% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$74.99
Open:
$75.46
24h Volume:
3.59M
Relative Volume:
0.80
Market Cap:
$44.71B
Revenue:
$5.54B
Net Income/Loss:
$4.18B
P/E Ratio:
10.89
EPS:
7
Net Cash Flow:
$623.10M
1W Performance:
-2.07%
1M Performance:
+0.24%
6M Performance:
+5.76%
1Y Performance:
-13.37%
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
EW
Edwards Lifesciences Corp
|
76.22 | 45.66B | 5.54B | 4.18B | 623.10M | 7.00 |
![]()
ABT
Abbott Laboratories
|
132.94 | 235.23B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
106.17 | 157.62B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
383.78 | 148.87B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
81.18 | 110.72B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-30-25 | Upgrade | Stifel | Hold → Buy |
Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
Jul-25-24 | Downgrade | Truist | Buy → Hold |
May-30-24 | Initiated | Goldman | Buy |
May-22-24 | Upgrade | Citigroup | Neutral → Buy |
May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
May-30-23 | Resumed | Morgan Stanley | Overweight |
Mar-29-23 | Initiated | UBS | Neutral |
Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-06-22 | Downgrade | Stifel | Buy → Hold |
Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
Oct-26-22 | Initiated | Mizuho | Buy |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-13-22 | Initiated | Truist | Buy |
Apr-06-22 | Initiated | Wolfe Research | Outperform |
Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Feb-02-22 | Upgrade | UBS | Neutral → Buy |
Jan-27-22 | Reiterated | Citigroup | Buy |
Jan-27-22 | Reiterated | Evercore ISI | Outperform |
Jan-27-22 | Reiterated | Raymond James | Outperform |
Jan-27-22 | Reiterated | Stifel | Buy |
Jan-27-22 | Reiterated | UBS | Neutral |
Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
Jul-30-21 | Reiterated | Deutsche Bank | Hold |
Jul-30-21 | Reiterated | Jefferies | Buy |
Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
Jul-30-21 | Reiterated | Oppenheimer | Outperform |
Jul-30-21 | Reiterated | Stifel | Buy |
Jul-30-21 | Reiterated | UBS | Neutral |
Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Neutral |
Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
Sep-11-20 | Initiated | Wolfe Research | Underperform |
Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Neutral |
Feb-06-20 | Resumed | BTIG Research | Neutral |
Jan-10-20 | Initiated | Oppenheimer | Outperform |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
Sep-23-19 | Initiated | Piper Jaffray | Overweight |
Jul-24-19 | Reiterated | BofA/Merrill | Buy |
Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-19 | Initiated | Deutsche Bank | Hold |
Nov-28-18 | Initiated | UBS | Neutral |
Oct-16-18 | Initiated | Barclays | Underweight |
Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com
Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech
Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga
Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus
Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com
Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stock News - GuruFocus
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey
Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing
Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance
Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq
Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com
Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com
FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal
Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey
Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace
FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India
FDA approves Edwards Lifesciences’ TAVR therapy - Investing.com
Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey
Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq
Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey
Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks
Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus
Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance
Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com
Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com
Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):